Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.46 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.46 |
| ▸ | GJB2 | P29033 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443464 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL736485 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL5029670 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL1134708 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL182764 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL9291634 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL23646744 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL4391706 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL8940690 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 | |
| SCHEMBL258033 | 1.00 | GBA1 (0.59) | GBA1SLC2A1MAPK1LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 953 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119505154-A | Special cross-linking agent for flexible polyurethane foam and application thereof | 奥斯佳新材料技术研究(江苏)有限公司 | 2025-02-25 | — | — | CN | claimed |
| US-11938189-B2 | Compositions and methods for stabilizing protein-containing formulations | GENENTECH, INC (US) | 2024-03-26 | — | — | US | claimed |
| CN-117589998-A | Quantitative detection kit for insulin-like growth factor I variants | 融智生物科技（青岛）有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117589997-A | Quantitative detection method for IGF-1 variant | 融智生物科技（青岛）有限公司 | 2024-02-23 | — | — | CN | claimed |
| US-20240011108-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2024-01-11 | — | — | US | claimed |
| CN-117310182-A | Sample processing kit for detecting Cys C by MALDI-TOF MS and application thereof | 融智生物科技（青岛）有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-117310180-A | Sample processing method for detecting Cys C by MALDI-TOF MS and application thereof | 融智生物科技（青岛）有限公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230345944-A1 | Purified and Enhanced Hydrogen Peroxide Disinfecting Solution for the Rapid Inactivation of COVID-19 and Other Pathogens | SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT | 2023-11-02 | — | — | US | claimed |
| CN-116735697-A | Method for detecting human calbindin S100A8 by MALDI-TOF MS | 融智生物科技（青岛）有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116643051-A | Human calbindin S100A8 detection kit | 融智生物科技（青岛）有限公司 | 2023-08-25 | — | — | CN | claimed |
| US-20040180444-A1 | Control solution for photometric analysis | BIONOSTICS, INC. | 2004-09-16 | — | — | US | claimed |
| WO-2003106678-A1 | DNA AMPLIFICATION AND SEQUENCING IN COLLAPSIBLE EMULSIONS | NUCLEICS PTY LTD (AU) | 2003-12-24 | — | — | WO | claimed |
| WO-2003082242-A2 | HIGHLY AQUEOUS LIQUID CARRIER FORMULATIONS | BATTELLEPHARMA, INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-20030185762-A1 | Highly aqueous liquid carrier formulations | BATTELLE MEMORIAL INSTITUTE | 2003-10-02 | — | — | US | claimed |
| US-6610316-B2 | Deactivating pathogens; binding to detergent; removal | SHANBROM TECHNOLOGIES, LLC | 2003-08-26 | — | — | US | claimed |
| US-20030039673-A1 | Deactivating pathogens; binding to detergent; removal | SHANBROM TECHNOLOGIES, LLC | 2003-02-27 | — | — | US | claimed |
| EP-1011740-B1 | DISINFECTION BY PARTICLE-BOUND AND INSOLUBILIZED DETERGENTS | SHANBROM TECH LLC (US) | 2002-03-20 | — | — | EP | claimed |
| US-6328728-B1 | DRUG DELIVERY FROM ELECTROTRANSPORT DEVICE, DISSOLVING OR SUSPENSION INTENSIFIERS, AGAR BEADS, BUFFERS | ALZA CORPORATION | 2001-12-11 | — | — | US | claimed |
| US-5357636-A | Flexible protective medical gloves and methods for their use | DRESDNER JR KARL P (US) | 1994-10-25 | — | — | US | claimed |
| US-5335373-A | Protective medical gloves and methods for their use | DRESDNER JR KARL P (US) | 1994-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230345944-A1 | Purified and Enhanced Hydrogen Peroxide Disinfecting Solution for the Rapid Inactivation of COVID-19 and Other Pathogens | CAT, PRDX1, HAO2 | GBA1 4301/4885SLC2A1 4491/4885MAPK1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.